Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting challenges in businesses like orthopedics and surgery.
Good morning, and welcome to Johnson & Johnson's third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. If anyone has any objections, you may disconnect at ...